PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer  >>  Phase 3
Welcome,         Profile    Billing    Logout  

25 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
2009-011564-11: Trial of vaccine in HIV patients from 6 years old to older

 
3
NA
13-valent pneumococcal conjugate vaccine, 13vPnC, Pneumovax, Pneumovax
Wyeth Pharmaceuticals Inc. (a Pfizer Company), Wyeth Pharmaceuticals Inc. (a Pfizer Company)
Pneumococcal infection in HIV infected subjects
 
 
2012-005367-27: Evaluation of the immune response and safety of a booster dose of Pfizer\'s 13-valent pneumococcal conjugate vaccine in children primed with 2 doses of either GSK\'s 10-valent pneumococcal conjugate vaccine or Pfizer\'s 13- valent pneumococcal conjugate vaccine in the Slovak Republic

Ongoing
3
92
Europe
Prevenar 13, Prevenar 13, Prevenar 13
BIOVOMED, GSK
To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 11-12 months of age in subjects primed with 10Pn-PD-DiT vs those primed with PCV13.
 
 
2016-004123-23: Immunization of immunosuppressed patients – Knowledge, practices and serological response Pneumokokvaccination af nyretransplanterede patienter i immunmodulerende behandling og end-stage nyresyge patienter. Et randomiseret ikke-blindet fase 3 klinisk forsøg der undersøger immunresponset af 2 forskellige kombinationer af pneumokokvaccination ved nyretransplanterede patienter og end-stage nyresyge patienter.

Ongoing
3
200
Europe
Suspension for injection, Prevenar 13®, Pneumovax
Department of Infectious Diseases, Odense University Hospital, Department of Infectious Diseases, Odense University Hospital, Region of Southern Denmark
Immunoresponse on pneumococcal vaccination of kidney transplant recipients in immunomodulatory therapy or patients with end stage renal disease., The effect of pneumococcal vaccination of kidney transplant recipients in immunomodulatory therapy or patients with end stage renal disease., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
PROPEL, NCT02628886: Protecting From Pneumococcus in Early Life (The Trial)

Active, not recruiting
3
600
RoW
13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid, PCV13, placebo 0.9% sodium chloride plus tetanus toxoid, placebo, tetanus toxoid
London School of Hygiene and Tropical Medicine, WHO Pneumococcal Serology Reference Laboratory Institute of Child Health, BUGS Bioscience London Bioscience Innovation Centre 2 Royal College Street London
Pneumonia
02/19
12/20
2019-002542-20: Efficacité de la vaccination anti-pneumococcique en prime-boost chez les patients atteints de lymphome diffus à grandes cellules B traités par Rituximab en 1ère ligne Efficacité de la vaccination anti-pneumococcique en prime-boost chez les patients atteints de lymphome diffus à grandes cellules B traités par Rituximab en 1ère ligne

Not yet recruiting
3
36
Europe
Prevenar13®, Pneumovax®, Solution for injection, Prevenar13®, Pneumovax®
CHRU de TOURS, CHRU de TOURS
Patients atteints de lymphome diffus à grandes cellules B Patients atteints de lymphome diffus à grandes cellules B, Patients atteints de lymphome diffus à grandes cellules B Patients atteints de lymphome diffus à grandes cellules B, Diseases [C] - Cancer [C04]
 
 
2018-004279-11: A trial to evaluate the safety and immune response of a pneumococcal conjugate vaccine in adults 18 years of age and older, who have not previously received a pneumococcal vaccine

Not yet recruiting
3
3880
Europe
20-valent Pneumococcal Conjugate Vaccine (20vPnC), PF-06482077, PPSV23, Suspension for injection in pre-filled syringe, Suspension for injection, Solution for injection, Prevenar 13, Pneumococcal Polysaccharide Vaccine
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, Pfizer Inc., 235 East 42nd Street, New York, NY 10017
Pneumococcal Infections, Prevention of disease caused by a type of bacteria called Streptococcus pneumoniae (pneumococcal disease)., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2019-001789-13: A Study Exploring Whooping Cough Protection in Infants

Not yet recruiting
3
114
Europe
Imovax ® Polio, ComVac5® (Bharat Biotech), INFANRIX-HEXA, Prevenar 13, Solution for injection, Suspension for injection, Imovax ® Polio, INFANRIX-HEXA, Prevenar 13
Clinical Trials and Research Governance (CTRG), University of Oxford, Innovative Medicines Initiative, Bill and Melinda Gates Foundation
This study is going to focus on the immunisations against pertussis disease in previous healthy children, but the disease itself is not going to be study., Whooping Cough, Body processes [G] - Immune system processes [G12]
 
 
2018-004278-91: A trial to evaluate the safety and immune response of a pneumococcal conjugate vaccine in adults ?65 years old with previous pneumococcal vaccination

Not yet recruiting
3
875
Europe
20-valent Pneumococcal Conjugate Vaccine (20vPnC), PF-06482077, Suspension for injection in pre-filled syringe, Suspension for injection, Prevenar 13
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, Pfizer Inc., 235 East 42nd Street, New York, NY 10017
Pneumococcal Infections, Prevention of disease caused by a type of bacteria called Streptococcus pneumoniae (pneumococcal disease)., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2017-004915-38: Safety and Immunogenicity of V114 in Adults at Risk for Pneumococcal Disease Wieloośrodkowe, randomizowane badanie kliniczne fazy 3 prowadzone na zasadzie podwójnie ślepej próby z grupą kontrolną przyjmującą lek porównawczy mające na celu ocenę bezpieczeństwa, tolerancji i immunogenności stosowania V114, po którym 6 miesięcy później następuje podanie PNEUMOVAX™23 u immunokompetentnych dorosłych w wieku 18-49 ze zwiększonym ryzykiem zachorowania na chorobę pneumokokową (PNEU-DAY).

Not yet recruiting
3
1500
Europe
15-Valent Pneumococcal Conjugate Vaccine, V114, Suspension for injection in pre-filled syringe, Suspension for injection, Solution for injection in pre-filled syringe, Prevenar 13 suspension for injection, PNEUMOVAX™23
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Pneumococcal disease, Pneumococcal disease, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2018-004316-22: Safety and immunogenicity of V114 in healthy adults Seguridad e inmunogenicidad de V114 en adultos sanos.

Not yet recruiting
3
1200
Europe
15-Valent Pneumococcal Conjugate Vaccine, V114, Suspension for injection in pre-filled syringe, Prevenar 13
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Pneumococcal disease Enfermedad neumocócica, Pneumococcal disease Pneumococcal disease, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT03574389: A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

Completed
3
936
RoW
13vPnC, Hib
Pfizer
Pneumococcal Infections, Pneumococcal Conjugate Vaccine
08/21
10/23
NCT04546425 / 2019-003306-27: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Completed
3
1258
Europe, RoW
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Pfizer
Pneumococcal Disease
04/22
02/23
MET52, NCT03632720: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Completed
3
788
Europe
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, MenACYW Conjugate vaccine, Meningococcal group B vaccine, Bexsero®, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine, Infanrix hexa®, Human rotavirus RIX4414 strain vaccine, Rotarix®, Pneumococcal 13-valent polysaccharide conjugate vaccine, Prevenar 13®
Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
12/22
12/22
2019-003305-10: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Not yet recruiting
3
2000
US
20-valent pneumococcal conjugate vaccine (subcutaneous), 13-valent pneumococcal conjugate vaccine (subcutaneous)/Suspension for injection, Suspension for injection, Prevenar 13
Pfizer Inc., Pfizer Inc.
Pneumococcal disease, Pneumococcal infection, Diseases [C] - Virus Diseases [C02]
 
 
MET41, NCT03673462 / 2019-004459-35: Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Completed
3
2797
US
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
03/23
03/23
NCT03547271 / 2017-004731-36: Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Hourglass Jan 2023 - Dec 2023 : Data from trial for meningococcal infections
Completed
3
1660
Europe, RoW
MenACYW conjugate vaccine, MenQuadfi®, Meningococcal group A, C, W-135, and Y conjugate vaccine, Nimenrix®, DTaP-IPV-HB-Hib vaccine, Hexyon®/Hexacima®, Pneumococcal vaccine (13-valent), Prevenar 13®, Pneumococcal vaccine (10-valent), Synflorix®, MMR vaccine, M-M-RVAXPRO®
Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
05/23
05/23
NCT05408429 / 2021-006624-41: Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13

Completed
3
356
Europe
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Pfizer
Pneumococcal Disease
06/23
06/23
NCT05512819: A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan

Active, not recruiting
3
231
RoW
20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
Pfizer
Pneumococcal Disease
01/26
01/26
2019-000926-23: A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese infants and young children

Not yet recruiting
3
936
RoW
13-valent pneumococcal conjugate vaccine, Haemophilius influenza Type b Vaccine, Injection, Solution for injection, Prevenar 13/Prevnar 13
Pfizer, Inc., Pfizer Inc
Pneumococcal Infections, Pneumococcal Infection, Not possible to specify
 
 
MET55, NCT04143061 / 2020-004341-36: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa

Completed
3
1328
RoW
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, MenACYW conjugate vaccine, Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine, Menactra®, Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine, Quadri Meningo™, Hepatitis A vaccine, Avaxim 80®, Measles, Mumps, and Rubella Virus Vaccine (MMR), Priorix™, Pneumococcal 13-valent conjugate vaccine, Prevnar 13®, DTwP-HepB-Hib-IPV vaccine, Shan6®, EasySixTM, Varicella vaccine, Varilrix®
Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
01/23
01/23
NCT03621670 / 2016-003268-37: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Active, not recruiting
3
1200
US
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
GlaxoSmithKline
Infections, Meningococcal
10/24
10/24
NCT03537508 / 2018-001473-24: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Hourglass Jan 2023 - Dec 2023 : Data from P3 trial for meningococcal infections
Completed
3
2637
US
MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, MENVEO®, DTaP-IPV//Hib vaccine, Pentacel®, Pneumococcal 13-valent conjugate vaccine, PREVNAR 13®, Pentavalent rotavirus vaccine, RotaTeq®, Hepatitis B vaccine, ENGERIX-B®, Measles, mumps, rubella (MMR) vaccine, M-M-R® II, Varicella vaccine, VARIVAX®, Hepatitis A vaccine, HAVRIX®
Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
09/23
09/23
NCT05759520: Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

Recruiting
3
1800
RoW
13-valent pneumococcal conjugate vaccine (multivalent conjugate), Prevenar 13
Fosun Adgenvax Biopharmaceutical Co.,Ltd.
Streptococcus Pneumoniae Infection
06/25
06/25
MEQ00064, NCT05794230: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Recruiting
3
1528
RoW
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, MenACYW conjugate vaccine - MenQuadfi™, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Menactra®, Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV), BIOPOLIO® B1/3, Pneumoccocal Vaccine, Prevnar 13®, Measles, Mumps, and Rubella Vaccine live (MMR) - TRESIVAC®, TRESIVAC®, DTwP-HepB-Hib-IPV vaccine, EasySix™, DTaP-IPV-Hib-HepB vaccine, Hexaxim®, Hepatitis A vaccine - HAPIBEV™, HAPIBEV™, Rotavirus vaccine, RotaTeq®, Typhoid conjugate vaccine (TCV), Typbar TCV®, Measles vaccine - MeasBio®, MeasBio®, Varicella vaccine live - VARIPED®, VARIPED®, Varicella vaccine live - Onvara, Onvara, Measles, Mumps, and Rubella Vaccine live (MMR) - OMZYTA®, OMZYTA®, Hepatitis A vaccine - Avaxim 80 U, Avaxim 80 U
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
09/25
09/25
NCT03384589: CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study

Completed
2/3
248
Canada
PCV13, Prevnar 13
University of British Columbia, Canadian Immunization Research Network, Alberta Children's Hospital, Université de Montréal, IWK Health Centre, University of Calgary, Canadian Institutes of Health Research (CIHR)
Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection
03/23
03/23

Download Options